Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been assigned a consensus recommendation of “Moderate Buy” from the four ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $8.13.

ESPR has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday, December 12th. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday. They set a “neutral” rating and a $4.00 target price for the company. Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a report on Tuesday. They set an “overweight” rating and a $8.00 price target for the company. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BOKF NA acquired a new position in shares of Esperion Therapeutics during the second quarter valued at about $26,000. Traphagen Investment Advisors LLC acquired a new position in Esperion Therapeutics during the 3rd quarter worth approximately $27,000. Xponance Inc. bought a new position in Esperion Therapeutics in the second quarter worth approximately $28,000. National Bank of Canada FI grew its stake in Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,225 shares during the period. Finally, Sivia Capital Partners LLC bought a new stake in shares of Esperion Therapeutics during the second quarter valued at approximately $44,000. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Stock Up 5.6 %

NASDAQ ESPR opened at $2.46 on Wednesday. The company has a market capitalization of $484.71 million, a price-to-earnings ratio of -3.84 and a beta of 1.01. Esperion Therapeutics has a twelve month low of $1.58 and a twelve month high of $3.94. The stock has a fifty day simple moving average of $2.40 and a 200 day simple moving average of $2.22.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.